Kornimate/medical-research-clean huggingface dataset:
conduction abnormalities with severe aortic stenosis before and after transcatheter aortic valve replacement

Conditions: Bradycardia

Summary: most of the conduction abnormalities with tavr are usually detected during the procedure or during the following days of observation. little is known about the prevalence and timing of any conduction abnormalities that exist before (other than standard ecg) or after through long term cardiac monitoring.

each subject who fulfills the inclusion/exclusion criteria will be provided with zio patch for 2 weeks before tavr. immediately after the procedure, patients will be admitted per tavr protocol and will be on telemetry. data about their ecgs and any arrhythmias will be collected. upon discharge, patients will be provided with another zio patch for 2 weeks. at the 2-3 months follow up, subjects will be provided with a third zio patch for 2 weeks

Eligibility criteria:
inclusion criteria: 1. age \> 18 and \<90 years old 2. able to provide informed consent 3. willing to follow up at cleveland clinic (per tavr protocol) exclusion criteria: 1. prior cied (pacemaker or defibrillator) 2. unable to provide consent 3. unable to follow up at cleveland clinic per tavr protocol
parent perceptions of weight status: impact of a pilot intervention

Conditions: Obesity

Summary: this pilot study is a randomized controlled trial with an embedded cross sectional study exploring parental perceptions of their weight status and how it affects their perceptions of their child's weight status. this study uses an educational intervention in which parents are informed of their actual weight status and how it affects their child's health. we will study the effect of this intervention on the parent's perceptions of and level of concern for their own and their child's weight status.

pediatric obesity has tripled in the past 20 years. obesity prevention early in life is important and parental participation is essential. parents must recognize overweight in their child so health providers may engage them in a dialogue to change their child's diet and physical activity patterns, yet a large proportion of parents do not recognize that their child is overweight. parents' misperception of their overweight child's weight status presents a barrier to treating obesity. this pilot study is a randomized controlled trial with an embedded cross sectional study exploring parental perceptions of their weight status and how it affects their perceptions of their child's weight status. this study uses an educational intervention in which parents are informed of their actual weight status and how it affects their child's health. we will study the effect of this intervention on the parent's perceptions of and level of concern for their own and their child's weight status. our goal is to develop a primary care intervention that will enhance parental perceptions of overweight and motivation to make changes for their family. pilot data collected here will support an r21 exploratory/developmental clinical research grant in obesity or a centers for disease control (cdc) or robert wood johnson foundation (rwj) grant submission.

Eligibility criteria:
inclusion criteria: 1. boys and girls ages 3 to 13 years old presenting with at least one biological parent for a routine health maintenance exam (wcc) at the child health continuity clinic will be eligible. parents must be able and willing to have their height and weight measured at the clinic exclusion criteria: 1. child has previously been referred to a nutritionist/dietician or specialized clinic/program for weight management 2. child is currently being treated for failure to thrive 3. child is on parenteral nutrition 4. child is on chronic systemic steroid therapy 5. child is non-mobile/wheelchair bound 6. the family has previously enrolled into the study with a prior sibling 7. family is unable to be contacted at home 8. presenting parent cannot speak and read english or spanish at at least a 5th grade level

Keywords: obesity weight perceptions
the role of laserpuncture for prevention of nausea and vomiting post strabismus surgery with general anesthesia in adult patients

Conditions: Nausea and Vomiting, Postoperative

Summary: this study to determine the effectiveness of a combination of pre-surgical laserpuncture with standard anti-emetic therapy for ponv symptoms in adult patients after strabismus surgery under general anesthesia compared to a combination of pre-surgical placebo laserpuncture with standard anti-emetic therapy. research design using a double blinded randomized controlled trial (rct) where research subjects and data takers who will be disguised. the research will be carried out in the operation and inpatient room, kirana building, rsupn dr. cipto mangunkusumo (rscm) with research subjects as adult patients undergoing strabismus surgery under general anesthesia. assessment of nausea and vomiting using avs ( analog visual scale) consists of scoring using a score from 1-5 which indicates the severity of nausea and vomiting.

this clinical trial is to evaluate the role of laserpuncture as a prevention of nausea and vomiting in adult patients after strabismus surgery under general anesthesia. participants are 32 males/females aged 18-59 years. they will be divided into 2 groups: (1) group laserpuncture and (2) sham laserpuncture. the study intervention was performed 30 minutes before surgery. the primary outcome in this study was the incidence of postoperative nausea and vomiting.

Eligibility criteria:
inclusion criteria: 1. adult patients aged 18-59 years. 2. patients undergoing simple strabismus surgery involving no more than two muscles without transposition under general anesthesia. 3. meets the asa (american society of anesthesiologists) score of 1-2. 4. complete the surgical preparations according to the presedation sheet. 5. sign the informed consent sheet. 6. patients who can communicate with the research team. 7. patients undergoing surgery \<3 hours. exclusion criteria: 1. the patient is pregnant. 2. patients who have a history of drug or drug abuse. 3. patients with hypersensitivity to laser light. 4. there are wounds or skin disorders at the radiation site (skin tb, sle(systemic lupus erythematosus) skin 5. patients who have gastrointestinal diseases (intestinal obstruction, peristaltic disorders gastrointestinal tract, gastroenteritis, irritable bowel syndrome, dyspepsia,gastroesophageal reflux disease/gerd, appendicitis, hepatitis, cholecystitis, inflammatory bowel synchrome, pancreatitis, peptic ulcer, peritonitis, food poisoning). 6. patients with metabolic diseases (acid-base imbalance, metabolic diseases calcium, glucose metabolism disease, hyperlactemia, mitochondrial disease, phenylketonuria) 7. patients with conditions of high intracranial pressure, head trauma, migraines, disease with symptoms of seizures, vestibular diseases, malignancies, mental and psychogenic diseases, diseases arising from consumption of drugs, nephrolithiasis, other kidney diseases, myocardial infarction, as well as the occurrence of nausea and vomiting before surgery. 8. infection accompanied by high fever (temperature \>38°c)
89zr-dfo-girentuximab expanded access program (eap)

Conditions: Clear Cell Renal Cell Carcinoma

Summary: the purpose of this expanded access program (eap) is to enable the use of 89zr-dfo-girentuximab with positron emission tomography/computed tomography (pet/ct) imaging to non-invasively detect carbonic anhydrase 9 (caix)-expressing clear cell renal cell carcinoma (ccrcc) in patients with renal masses as determined by conventional imaging.


Eligibility criteria:
inclusion criteria: 1. written and voluntarily given informed consent. 2. male or female ≥ 18 years of age. 3. imaging evidence of renal mass(es) obtained from conventional diagnostic imaging with ct or mri (without and with contrast enhancement) based on national standards that is not older than 90 days on day 0, and that was performed before any screening procedure. 4. negative urine/serum pregnancy tests in female patients of childbearing potential. 5. consent to practice highly effective contraception until a minimum of 42 days after iv 89zr-dfo-girentuximab administration. exclusion criteria: 1. renal mass known to be a metastasis of another primary tumor. 2. active non-renal malignancy requiring therapy during and up to eot visit. 3. radiotherapy or immunotherapy within 4 weeks (28 days) prior to the planned administration of 89zr-dfo-girentuximab or continuing adverse effects (\> grade 1 using common terminology criteria for adverse events \[ctcae\] version 5.0) from such therapy. 4. planned antineoplastic therapies (for the period between iv administration of 89zr-dfo-girentuximab and imaging). 5. previous administration of any radionuclide within 10 of its half-lives before day 0. 6. serious non-malignant disease (e.g., psychiatric, infectious, autoimmune, or metabolic), that may interfere with the objectives of the program or with the safety or compliance of the subject, as judged by the investigator. 7. mental impairment that may compromise the ability to give informed consent and comply with the requirements of the program. 8. exposure to any experimental diagnostic or therapeutic drug within 30 days from the date of planned administration of 89zr-dfo-girentuximab. 9. women who are pregnant or breastfeeding. 10. known hypersensitivity to girentuximab or dfo (desferoxamine).

Keywords: clear cell renal cell carcinoma pet/ct imaging 89zr-girentuximab
clinical and immunological outcomes of living and deceased donor transplantation

Conditions: Transplant Recipient (Kidney)

Summary: this is a retrospective, prospective, single-centre, non-pharmacological observational study. the primary objective is to investigate the long-term prognosis of the kidney transplant function of different types of donors.

it provides for the systematic collection of clinical information of patients undergoing kidney transplantation from 01/01/2017 until the ethics committee approves the study and the director general of the irccs issues the authorisation. data collection will continue for 9 years after the start of the study. patients participating in the prospective part will be treated according to clinical practice, in accordance with the judgement of the physician and the information reported in the technical data sheet of each individual product of any concomitant therapies administered according to clinical practice. there are no additional study-specific visits/examinations for enrolled patients and any data recorded for the purposes of the study is collected for care purposes during the patient's normal course of treatment.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * kidney transplant recipient from any donor. * acquisition of informed consent to study participation and data processing. exclusion criteria: -
pilot study comparing effects of xanomeline alone to xanomeline plus trospium

Conditions: Schizophrenia

Summary: this study is intended to determine whether the addition of trospium chloride to xanomeline tartrate will ameliorate the peripheral cholinergic side effects that have been previously experienced with xanomeline tartrate when administered alone.

in this inpatient study, volunteers will received either xanomeline alone, or xanomeline plus trospium for 7 days. subjects will report cholinergic side effects daily via visual analog scales, for each of nausea, vomiting, diarrhea, sweating and excessive salivation. clinician administered scales will also be administered daily for assessment of the same cholinergic side effects.

Eligibility criteria:
inclusion criteria: * female subjects must be postmenopausal (at least 2 years prior to dosing) or agree to use an acceptable form of birth control from screening until 14 days after completion of the study. if on birth control pills, have been on a stable dose for≥12 months. * good general health * ability to give informed consent and understand verbal instructions * willingness to spend 10 days in an in-patient facility exclusion criteria: * history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results. (subjects with any history of resolved cancer that is \>5 years passed can be included.) * body mass index \ 40 kg/m2 * history of or high risk of urinary retention, gastric retention, or narrow-angle glaucoma * history of alcohol or drug abuse within the last 24 months, or current abuse as determined by urine toxicology screen * clinically significant abnormal finding on the physical exam, medical history, ecg, or clinical laboratory results at screening * has participated in another clinical trial within 90 days prior to the first dose of study medication * needs to take any prescription medication besides the investigational product or those specifically noted above. use of any vitamins, herbs, supplements, or over the counter medications are excluded within one week of enrollment, and during the course of the trial. specifically, subjects may not take benadryl® for one week prior and during the course of the study. * use of any tobacco products within the past 30 days * previous positive test for hiv 1 and/or 2, or hepatitis a, b, or c, or a positive test obtained at screening.
depocyte in the treatment of cns relapse in patients with lymphoblastic leucemia or very aggressive lymphoma

Conditions: Lymphoblastic Leukemia; Lymphoma

Summary: the first purpose is to confirm or not the efficacy of only one administration of depocyte®.

it is a clinical study multicenter, prospective, open label trial, uncontrolled and nonrandomized

Eligibility criteria:
inclusion criteria: * patients with acute lymphoblastic leukemia or very aggressive non-hodgkin-lymphoma (burkitt/burkitt-like) and cns relapse. cns involvement must be demonstrated by: * a positive ventricular or lumbar csf cytology defined as csf cell counts \> 5/µl (19/3 cells), obtained within 10 days prior to inclusion or * characteristic signs and symptoms of neoplastic meningitis plus an mri or ct scan indicating the presence of meningeal involvement. patients with combined relapse in cns and other locations may be included in case that systemic therapy with cns active drugs (hdmtx;hdac, thiotepa) can be postponed for at least 2 weeks. * karnofsky \>60% * age \>18 years old * recovery from grade iii/iv toxicities attributable to prior treatment with the exception of hematotoxicity. * no severe heart, lung, liver or kidney dysfunction. * the patient or guardian must be competent to provide informed consent and must provide written informed consent prior to the initiation of study procedures exclusion criteria: * failure (as defined by no clearance of the csf) to \> 1 dose of prior intrathecal mtx or cytarabine or triple (mtx, arac, dexamethasone) therapy * history of previous severe neurotoxicity (grade iii-iv) attributed to intrathecal therapy or systemic high-dose therapy with methotrexate or cytarabine (vincristine induced peripheral neuropathy is accepted) * prior cns relapse \< 1 month before * uncontrolled infection * the patient must not be pregnant or breast feeding. if the patient is a female of child-bearing potential she must have a negative (urine or serum) pregnancy test and be using effective methods to prevent pregnancy

Keywords: acute lymphoblastic leucemia aggressive non-hodgkin-lymphoma cns relapse cytarabine liposome
augmented bladder tumor detection using real time based artificial intelligence

Conditions: Bladder Cancer; Cystoscopy; Artificial Intelligence

Summary: today the standard for the diagnosis and monitoring of bladder tumors is bladder endoscopy. the performance of this exam is not perfect. with this work, based on artificial intelligence, the investigators wish to combine endoscopy with a complementary diagnostic tool in order to improve patient care. the main objective will be to reduce diagnostic errors / wanderings in patients treated or followed for bladder tumors, by imposing a new standard of diagnostic bladder mapping (high ppv and vpn, high precision)(primary purpose diagnostic). the secondary objective will be to homogenize and systematize the descriptive part of the lesions, and to use ai to better characterize tumor aggressiveness. the final objective being to validate a new precision tool (diagnostic companion) essential for developing and standardizing the therapeutic management of bladder tumors (correcting inter-observer heterogeneity). in this project, video frame will be first extracted from our dataset of cystoscopy videos hosted in in the next cloud recherche. selected medical image will be segmented and analyzed using our pre-trained cnn model with a feature detection algorithm to obtain features. data will be analyzed on both patient and lesion levels. the study will assess the bladder-pad accuracy on the detection of bladder tumors, and its ability to predict tumor risk of recurrence and progression.


Eligibility criteria:
inclusion criteria: * unifocal primary or recurrent suspected bladder cancer with tumor size less or equal than 3 cm * multifocal primary or recurrent suspected bladder cancer less or equal than 5 lesions and with tumor size less or equal than 3 cm. exclusion criteria: * evidence of more than 5 tumors or more than 3 cm * computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (ct2 or higher) * computed tomography/magnetic resonance evidence of distant metastases (lymphatic or organic) * exclusion criteria will include gross hematuria and bacillus calmette-guerin (bcg) treatment or chemotherapy within 3 months of inclusion * an exception will be made if patients had received only a single course of chemotherapy immediately following tur * patients objecting to the use of their data in the context of research.

Keywords: bladder cancer cystoscopy artificial intelligence
development and validation of a therapeutic decision aid in ectopic pregnancy: geudecid study

Conditions: To Validate a Decision Aid for Ectopic Pregnancy

Summary: the aim's study is to validate a therapeutic aid in women with a less active ectopic pregnancy. a prospective recrutement of 100 women will be performed in 16 different hospitals in france. the decision aid will be used and a questionnaire about its usefulness, comprehension and satisfaction will be given to women and doctors.

in less active ectopic pregnancy, two treatments are possible: a medical treatment using methotrexate or a surgical management. a discret choice experiment study was performed to reveal women's preferences between these two options. in conclusion, calculated preferences are 47.5 and 52.5%, revealing a difficult choice for women. this study also lead to identify the main attributes important to make the choice. we were then able to create a therapeutic decision aid to help this shared decision. this aid needs to be validated, following steps for validation. this study is the last step in women in situation of less active ectopic pregnancy.

Eligibility criteria:
inclusion criteria: * women who speak and read french * not opposed to participate to the research * with a tubal ectopic pregnancy visible at sonography * with an hcg rate under 10 000ui/ml exclusion criteria: * cardiac activity present in the embryo * hemoperitoin * hemodynamic instability * spontaneous pelvic pain * contre indication to methotrexate * protected adult patient

Keywords: decision aid shared decision making less active ectopic pregnancy methotrexate medical treatment surgery
tips combined with lenvatinib and pd-1 inhibitor for advanced hcc with main trunk pvtt

Conditions: Hepatocellular Carcinoma; Portal Vein Tumor Thrombus; Systemic Therapy

Summary: hepatocellular carcinoma (hcc) with main trunk portal vein tumor thrombus (pvtt) has poor prognosis. the main lethiferous factor is the upper gastrointestinal hemorrhage by pvtt-related portal hypertension, then the second is the tumor-caused death. it is vital to prevent the portal hypertension by pvtt.

portal hypertension by main trunk portal vein tumor thrombus (pvtt) is a severe disease. patients usually die of gastrointestinal hemorrhage rather than tumor progression. it is vital to prevent the portal hypertension. transjugular intrahepatic portosystemic shunt (tips) is an effective method to alleviate the portal pressure. then the risk of gastrointestinal hemorrhage is decreased which provides an opportunity for system therapy. in this study, the investigators explore the tips combined with lenvatinib and pd-1 inhibitor for advanced hepatocellular carcinoma with main trunk portal vein tumor thrombus. the investigators aim to add clinical evidence for this subtype of advanced hcc.

Eligibility criteria:
inclusion criteria: 1. diagnosis of primary hcc, confirmed histologically or clinically according to the criteria of the american association for the study of liver diseases; 2. presence of pvtt with iii-iv grade by cheng's criteria; 3. having pvtt induced portal hypertension; 4. with or without pvtt induced acute variceal bleeding; 5. metastases with limited five sites and no more two organs involved; 6. number of intrahepatic tumors were no more than five; 7. receipt of lenvatinib and pd-1 inhibitor as the first-line systemic therapy; 8. classified as child-pugh class a or b and having an eastern cooperative oncology group (ecog) performance status of 0 or 2; 9. no history of other malignancies; 10. agreed to participated in this clinical trial; 11. hemameba ≥3.0 x109/l, neutrophil ≥1.5x109/l, hemoglobin≥10.0 g/l, platelet≥100x 109/l, alt; ast; bilirubin ≤1.5-fold normal, gfr≥60ml/min. exclusion criteria: 1. recurrent hcc; 2. pvtt at i-ii grade by cheng's criteria; 3. age \ 75 years; 4. advanced hcc with more than five metastases; 5. number of intrahepatic tumors were more than five; 6. no response to lenvatinib; 7. life expectancy less than 3 months.

Keywords: advanced hepatocellular carcinoma lenvatinib sintilimab camrelizumab tislelizumab transjugular intrahepatic portosystemic shunt main trunk portal vein tumor thrombus